SS Innovations International Inc. (NASDAQ: SSII) is pursuing a strategy to broaden access to robotic surgery by focusing on affordability and accessibility, according to a recent interview with founder, chairman and CEO Dr. Sudhir Srivastava. The company's SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery. With over 200 robotic systems installed and more than 11,700 procedures completed, including over 170 telesurgeries, the company is positioning itself as a key player in the surgical robotics market.
Dr. Srivastava emphasized that rather than competing directly with existing platforms, SS Innovations aims to expand access to hospitals and patients that have historically been unable to adopt robotic surgery due to high equipment costs. The company's long-term product roadmap includes artificial intelligence, automation, and new robotic platforms. Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely.
The company is pursuing FDA and European regulatory approvals while expanding into additional international markets. For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results, as highlighted in the Medsider interview with Dr. Srivastava.
More details are available in the company's newsroom at https://ibn.fm/SSII. SS Innovations International Inc. is a developer of innovative surgical robotic technologies focused on making robotic surgery more accessible globally.
